A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice

Virology

Volumn 394, Issue 2, 2009, Pages 249-258

  Valdés, Iris ^a   Bernardo, Lidice ^b   Gil, Lázaro ^a   Pavón, Alekis ^b   Lazo, Laura ^a   López, Carlos ^a   Romero, Yaremis ^a   Menendez, Ivón ^a   Falcón, Viviana ^a   Betancourt, Lázaro ^a   Martín, Jorge ^a   Chinea, Glay ^a   Silva, Ricardo ^a   Guzmán, María G ^b   Guillén, Gerardo ^a   Hermida, Lisset ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^b INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

Author keywords

Capsid; Cell mediated immunity; Dengue virus; Domain III; Neutralizing antibodies; Oligonucleotides; Recombinant protein; Vaccine

Indexed keywords

CHIMERIC PROTEIN; GAMMA INTERFERON; HYBRID PROTEIN; INTERLEUKIN 4; OLIGODEOXYNUCLEOTIDE; RECOMBINANT DOMAIN III CAPSID CHIMERIC PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DENGUE; DENGUE VIRUS; DRUG SCREENING; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOMODULATION; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PURIFICATION;

ANIMALS; ANTIGENS, VIRAL; BASE SEQUENCE; CAPSID PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CLONING, MOLECULAR; DENGUE; DENGUE VIRUS; FEMALE; INTERFERON-GAMMA; INTERLEUKIN-4; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON, TRANSMISSION; MULTIPROTEIN COMPLEXES; PLASMIDS; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; VIRAL FUSION PROTEINS;

DENGUE VIRUS; ESCHERICHIA COLI; MIRIDAE; MUS;

EID: 70449527814     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2009.08.029     Document Type: Article

References (49)

1. Ackerman A.L., Giodini A., and Cresswell P. A role for the endoplasmic reticulum protein retrotranslocation machinery during crosspresentation by dendritic cells. Immunity 25 (2006) 607-617
2. Aihara H., Takasaki T., Matsutani T., Suzuki R., and Kurane I. Establishment and characterization of Japanese encephalitis virus-specific human CD4 T-cell clones: flavivirus cross-reactivity, protein recognition, and cytotoxic activity. J. Virol. 72 (1998) 8032-8036
3. Babu J.P., Pattnaik P., Gupta N., Shrivastava A., Khan M., and Lakshmana Rao P.V. Immunogenicity of a recombinant envelope domain III protein of dengue virus type-4 with various adjuvants in mice. Vaccine 26 (2008) 4655-4663
4. Bernardo L., Izquierdo A., Álvarez M., Rosario D., Prado I., López C., Martínez R., Castro J., Santana E., Hermida L., Guillen G., and Guzmán M.G. Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates. Antiviral Res. 80 (2008) 194-199
5. Berrios V., Kurane I., and Ennis F.A. Immunomodulatory effects of IL-7 on dengue virus-specific cytotoxic CD4+T cell clones. Immunol. Invest. 25 (1996) 231-240
6. Bhamarapravati N., and Sutee Y. Live attenuated tetravalent dengue vaccine. Vaccine 18 (2000) 44-47
7. Bullock W.O., Fernández J.M., and Short J.M. XL1-blue: a high efficiency plasmid transforming recA Escherichia coli strain with betagalactosidase selection. BioTechniques 4 (1987) 376-378
8. Chaung H.C. CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy. Int. Immunopharmacol. 6 (2006) 1586-1596
9. Chen Y., Maguire T., and Marks R.M. Demonstration of binding of dengue virus envelope protein to target cells. J. Virol. 70 (1996) 8765-8772
10. Chen S., Yu M., Jiang T., Deng Y., Qin C., and Qin E. Induction of tetravalent protective immunity against four dengue serotypes by the tandem domain III of the envelope protein. DNA Cell Biol. 26 (2007) 361-367
11. Chin J.F., Chu J.J., and Ng M.L. The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry. Microbes Infect. 9 (2007) 1-6
12. Chung Y.C., Ho M.S., Wu J.C., Chen W.J., Huang J.H., Chou S.T., and Hu Y.C. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 26 (2008) 1855-1862
13. Churdboonchart V., Bhamarapravati N., and Peampramprecha S. Antibodies against dengue viral proteins in primary and secondary dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 44 (1991) 481-493
14. Crill W.D., and Roehrig J.T. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to vero cells. J. Virol. 75 (2001) 7769-7773
15. Gagnon S.J., Zeng W., Kurane I., and Ennis F.A. Identification of two epitopes on the dengue 4 virus capsid protein recognized by a serotype-specific and a panel of serotype-cross-reactive human CD4+ cytotoxic T-lymphocytes clones. J. Virol. 70 (1996) 141-147
16. Gagnon S.J., Ennis F.A., and Rothman A.L. Bystander target cell lysis and cytokine production by dengue virus-specific human CD4+cytotoxic T-lymphocytes clones. J. Virol. 73 (1999) 3623-3629
17. Gil L., López C., Blanco A., Lazo L., Martín J., Valdés I., Romero Y., Figueroa Y., Guillén G., and Hermida L. The cellular immune response plays an important role in protecting against dengue virus in the mouse encephalitis model. Viral Immunol. 22 (2009) 23-29
18. Green S., Kurane I., Eldelman R., Tacket C.O., Eckels K.H., Vaughn D.W., Hoke C.H., and Ennis F.A. Dengue virus-specific human CD4+T-lymphocyte responses in a recipient of an experimental live-attenuated dengue virus type 1 vaccine: bulk culture proliferation, clonal analysis and precursor frequency determination. J. Virol. 67 (1993) 5962-5967
19. Gubler D.J. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol. 10 (2002) 100-103
20. Guzmán M.G., Rodríguez R., Rodríguez R., Hermida H., Álvarez M., Lazo L., Muné M., Rosario D., Valdés K., Vázquez S., Martínez R., Serrano T., Paez R., Espinosa R., Pumariega T., and Guillén G. Induction of neutralizing antibodies and partial protection from viral challenge in Macaca fascicularis immunized with recombinant dengue 4 virus envelope glycoprotein expressed in Pichia pastoris. Am. J. Trop. Med. Hyg. 69 (2003) 129-134
21. Hermida L., Rodríguez R., Lazo L., Bernardo L., Silva R., Zulueta A., López C., Martín J., Valdés I., del Rosario D., Guillén G., and Guzmán M.G. A fragment of the envelope protein from dengue-1 virus, fused in two different sites of the meningococcal P64k protein carrier, induces a functional immune response in mice. Biotechnol. Appl. Biochem. 39 (2004) 107-114
22. Hermida L., Rodríguez R., Lazo L., Silva R., Zulueta A., Chinea G., López C., Guzmán M.G., and Guillén G. A dengue-2 Envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice. J. Virol. Methods 115 (2004) 41-49
23. Hermida L., Bernardo L., Martín J., Álvarez M., Prado I., López C., Sierra B., Martínez R., Rodríguez R., Zulueta A., Pérez A.B., Lazo L., Rosario D., Guillén G., and Guzmán M.G. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 24 (2006) 3165-3171
24. Huerta V., Chinea G., Fleitas N., Sarría M., Sánchez J., Toledo P., and Padrón G. Characterization of the interaction of domain III of the envelope protein of dengue virus with putative receptors from CHO cells. Virus Res. 137 (2008) 225-234
25. Hung J.J., Hsieh M.T., Young M.J., Kao C.L., King C.C., and Chang W. An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells. J. Virol. 78 (2004) 378-388
26. Izquierdo A., Bernardo L., Martín J., Santana E., Hermida L., Guillén G., and Guzmán M.G. Serotype-specificity of recombinant fusion proteins containing domain III of dengue virus. Virus Res. 138 (2008) 135-138
27. Kaufman B.M., Summers P.L., Dubois D.R., and Eckels K.H. Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. Am. J. Trop. Med. Hyg. 36 (1987) 427-434
28. Kuhn R.J., Zhang W., Rossmann M.G., Pletnev S.V., Corver J., Lenches E., Jones C.T., Mukhopadhyay S., Chipman P.R., Strauss E.G., Baker T.S., and Strauss J.H. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108 (2002) 717-725
29. Lazo L., Hermida L., Zulueta A., Sánchez J., López C., Silva R., Guillén G., and Guzmán M.G. A recombinant capsid protein from Dengue-2 induces protection in mice against homologous virus. Vaccine 25 (2007) 1064-1070
30. López C., Gil L., Lazo L., Menéndez I., Marcos E., Sánchez J., Valdés I., Falcón V., de la Rosa M.C., Márquez G., Guillén G., and Hermida L. The in vitro assembly of nucleocapsid-like particles from the purified recombinant capsid protein of dengue 2. Arch. Virol. 154 (2009) 695-698
31. Morens D.M., Halstead S.B., and Repik P.M. Simplified plaque reduction assay for dengue viruses by semimicro methods in BHK 21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization. J. Clin. Microbiol. 22 (1985) 250-254
32. Mukhopadhyay S., Kim B.S., Chipman P.R., Rossmann M.G., and Kuhn R.J. Structure of West Nile virus. Science 302 (2003) 248
33. Pupo Antunez M., Rodriguez H., Vazquez S., Vilaseca J.C., Alvarez M., Otero A., and Guzman G. Monoclonal antibodies raised to the dengue-2 virus (Cuban: A15 strain) which recognize viral structural proteins. Hybridoma 16 (1997) 347-353
34. Putnak R.J., Coller B.A., Voss G., Vaughn D.W., Clements D., Peters I., Bignami G., Houng H.S., Chen R.C., Barvir D.A., Seriwatana J., Cayphas S., Garçon N., Gheysen D., Kanesa-Thasan N., McDonell M., Humphreys T., Eckels K.H., Prieels J.P., and Innis B.L. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 23 (2005) 4442-4452
35. Rey F.A., Heinz F.X., and Mandl C. The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution. Nature 375 (1995) 291-298
36. Sabchareon A., Lang J., Chanthavanich P., Yoksan S., Forrat R., Attanath P., Sirivichayakul C., Pengsaa K., Pojjaroen-Anant C., Chambonneau L., Saluzzo J.F., and Bhamarapravati N. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am. J. Trop. Med. Hyg. 66 (2002) 264-272
37. Sabchareon A., Lang J., Chanthavanich P., Yoksan S., Forrat R., Attanath P., Sirivichayakul C., Pengsaa K., Pojjaroen-Anant C., Chambonneau L., Saluzzo J.F., and Bhamarapravati N. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five-to twelve-year-old Thai children. Pediatr. Infect. Dis. J. 23 (2004) 99-109
38. Sambrook J., Fritsch E.F., and Maniatis T. The molecular cloning. A laboratory manual. 2nd ed (1989), Cold Spring Harbor, New York Co
39. Sanger F., Niclen S., and Coulson A.R. DNA sequencing with chain terminating inhibitors. Proc. Natl. Acad. Sci. U.S.A. 74 (1977) 5463-5467
40. Shresta S., Kyle J.L., Snider H.M., Basavapatna M., Beatty P.R., and Harris E. Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T-and B-cell-dependent immunity are less critical. J. Virol. 78 (2004) 2701-2710
41. Silva, R., Selmán, M., Guillén, G., Herrera, L., Fernández, J.R., Novoa, L.I., Morales, J., Morera, V., González, S., Tamargo, B., del Valle, J., Caballero, E., Álvarez, A., Coizeau, E., Cruz, S., Musacchio, A., 1992. Nucleotide sequence coding for an outer membrane protein from Neisseria meningitidis and use of said protein in vaccine preparations, European Patent Application EP 0474313 A2.
42. Simasathien S., Thomas S.J., Watanaveeradej V., Nisalak A., Barberousse C., Innis B.L., Sun W., Putnak J.R., Eckels K.H., Hutagalung Y., Gibbons R.V., Zhang C., De La Barrera R., Jarman R.G., Chawachalasai W., and Mammen M.P.J. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. Am. J. Trop. Med. Hyg. 78 (2008) 426-433
43. Simmons M., Nelson W.M., Wu S.J., and Hayes C.G. Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. Am. J. Trop. Med. Hyg. 58 (1998) 655-662
44. Stephenson J.R. Understanding dengue pathogenesis: implications for vaccine design. Bull. World Health Organ. 83 (2005) 308-314
45. Takeshita F., Leifer C.A., Gursel I., Ishii K.J., Takeshita S., Gursel M., and Klinman D.M. Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J. Immunol. 167 (2001) 3555-3558
46. Valdés I., Hermida L., Martín J., Menéndez T., Gil L., Lazo L., Castro J., Niebla O., López C., Bernardo L., Sánchez J., Romero Y., Martínez R., Guzmán M.G., and Guillén G. Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitides. Vaccine 27 (2009) 995-1001
47. Van der Most R.G., Murali-Krishna K., Ahmed R., and Strauss J.H. Chimeric yellow fever/ dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell response. J. Virol. 4 (2000) 8094-8101
48. Yauch L.E., Zellweger R.M., Kotturi M.F., Qutubuddin A., Sidney J., Peters B., Prestwood T.R., Sette A., and Shresta S. A protective role for dengue virus-specific CD8+T cells. J. Immunol. 182 (2009) 4865-4873
49. Zulueta A., Hermida L., Lazo L., Valdés I., Rodríguez R., López C., Silva R., Rosario D., Martín J., Guzmán M.G., and Guillén G. The fusion site of envelope fragments from each serotype of dengue virus in the P64k protein, influence some parameters of the resulting chimeric construct. Biochem. Biophys. Res. Commun. 308 (2003) 619-626